Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE

ConclusionsBimekizumab treatment was associated with long-term sustained improvements in pain and fatigue, reducing overall impact of PsA on patients. Physical function and quality of life improved up to 3  years.Trial registrationClinicalTrials.gov,https://clinicaltrials.gov, NCT02969525, NCT03347110.
Source: Rheumatology - Category: Rheumatology Source Type: research